---
title: "Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286092762.md"
description: "Bernstein analyst Courtney Breen has reaffirmed a Hold rating on Moderna (MRNA) with a price target of $45.00, while the shares closed at $52.88. Breen, who focuses on the Healthcare sector, has an average return of 16.0% and an 82.00% success rate. Additionally, Jefferies analyst Andrew Tsai also issued a Hold rating on Moderna, while Piper Sandler reiterated a Buy rating on May 8."
datetime: "2026-05-12T11:45:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286092762.md)
  - [en](https://longbridge.com/en/news/286092762.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286092762.md)
---

# Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday and set a price target of $45.00. The company’s shares closed yesterday at $52.88.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Merck & Company. According to TipRanks, Breen has an average return of 16.0% and an 82.00% success rate on recommended stocks.

In addition to Bernstein, Moderna also received a Hold from Jefferies’s Andrew Tsai in a report issued today. However, on May 8, Piper Sandler reiterated a Buy rating on Moderna (NASDAQ: MRNA).

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Assessing Moderna (MRNA) Valuation After Flu Vaccine Data And Hantavirus Program Interest](https://longbridge.com/en/news/286642428.md)
- [Hantavirus: Is there a risk of another pandemic?](https://longbridge.com/en/news/286634066.md)
- [Moderna Recognized by TIME as One of the World's Most Impactful Companies](https://longbridge.com/en/news/286159154.md)
- [Key facts: Moderna shows 26.6% vs flu; hantavirus preclin, no trials](https://longbridge.com/en/news/285820887.md)
- [Moderna Updates Bylaws and Confirms Governance Leadership](https://longbridge.com/en/news/285924997.md)